ArticleThe Journal of biological chemistry2008
Effect of FGF-binding protein 3 on vascular permeability.
Article in The Journal of biological chemistry, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- HcN13, a Fibroblast Growth Factor Binding Protein, Is Associated with Shell Formation in Hyriopsis cumingii.Marine biotechnology (New York, N.Y.) · 2025Article
- Fibroblast Growth Factor Binding Protein 3 (FGFBP3) impacts carbohydrate and lipid metabolism.Scientific reports · 2018Article
- FGF binding proteins (FGFBPs): Modulators of FGF signaling in the developing, adult, and stressed nervous system.Biochimica et biophysica acta. Molecular basis of disease · 2018Review
- Blood Pressure Control by a Secreted FGFBP1 (Fibroblast Growth Factor-Binding Protein).Hypertension (Dallas, Tex. : 1979) · 2018Article
- Chemopreventive effect of Korean Angelica root extract on TRAMP carcinogenesis and integrative "omic" profiling of affected neuroendocrine carcinomas.Molecular carcinogenesis · 2015Article
- Angiopoietin-1 prevents severe bleeding complications induced by heparin-like drugs and fibroblast growth factor-2 in mice.American journal of physiology. Heart and circulatory physiology · 2015Article
- Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action.Chemical science · 2015Article
- Role of the nuclear receptor coactivator AIB1/SRC-3 in angiogenesis and wound healing.The American journal of pathology · 2012Article
- Impact of fibroblast growth factor-binding protein-1 expression on angiogenesis and wound healing.The American journal of pathology · 2011Article
- Quantitative three-dimensional imaging of live avian embryonic morphogenesis via micro-computed tomography.Developmental dynamics : an official publication of the American Association of Anatomists · 2011Article
- A distinct role for secreted fibroblast growth factor-binding proteins in development.Proceedings of the National Academy of Sciences of the United States of America · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Fibroblast growth factor-binding protein 1 (FGF-BP1 is BP1) is involved in the regulation of embryonic development, tumor growth, and angiogenesis by mobilizing endogenous FGFs from their extracellular matrix storage. Here we describe a new member of the FGF-BP family, human BP3. We show that the hBP3 protein is secreted from cells, binds to FGF2 in vitro and in intact cells, and inhibits FGF2 binding to heparin. To determine the function of hBP3 in vivo, hBP3 was transiently expressed in chicken embryos and resulted in > 50% lethality within 24 h because of vascular leakage. The onset of vascular permeability was monitored by recording the extravasation kinetics of FITC-labeled 40-kDa dextran microperfused into the vitelline vein of 3-day-old embryos. Vascular permeability increased as early as 8 h after expression of hBP3. The increased vascular permeability caused by hBP3 was prevented by treatment of embryos with PD173074, a selective FGFR kinase inhibitor. Interestingly, a C-terminal 66-amino acid fragment (C66) of hBP3, which contains the predicted FGF binding domain, still inhibited binding of FGF2 to heparin similar to full-length hBP3. However, expression of the C66 fragment did not increase vascular permeability on its own, but required the administration of exogenous FGF2 protein. We conclude that the FGF binding domain and the heparin binding domain are necessary for the hBP3 interaction with endogenous FGF and the activation of FGFR signaling in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.